PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington ’s disease

Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine RG6042 (formerly known as IONIS-HTTRx) for the treatment of people with Huntington’s disease (HD).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news